Published in
Elsevier, European Journal of Cancer, (82), p. 237-246
DOI: 10.1016/j.ejca.2017.05.010
Links
Tools
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
Journal article published in 2017 by
J. Gligorov 
,
B. Ataseven,
M. Verrill,
M. De Laurentiis,
K. H. Jung,
H. A. Azim,
N. Al-Sakaff,
S. Lauer,
M. Shing,
X. Pivot,
Dhurata Koroveshi,
Kamel Bouzid,
Monica Casalnuovo,
Diana Cascallar,
Ernesto Pablo Korbenfeld
and other authors.
,
B. Ataseven,
M. Verrill,
M. De Laurentiis,
K. H. Jung,
H. A. Azim,
N. Al-Sakaff,
S. Lauer,
M. Shing,
X. Pivot,
Dhurata Koroveshi,
Kamel Bouzid,
Monica Casalnuovo,
Diana Cascallar,
Ernesto Pablo Korbenfeld
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 